Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Elucidation of the Signaling Pathways involved in Human Cerebral Cavernous Malformations for the purpose of Therapeutics

FY 2019-20

Summary
"Cerebral Cavernous Malformations (CCMs) are recurrent malformations (lesions) of the brain and spinal cord caused by leaking blood vessels. CCMs have symptoms that mimic neurodegeneration, and predisposes patients to a lifetime risk of stroke and epilepsy. The only available treatment is brain surgery to remove the lesion, but this is high risk and sometimes impossible if the lesions are deeper in the brain, which highlights a need for new treatments that are more effective, lower risk, and potentially preventative. Loss-of-function mutations in the CCM1, CCM2, and CCM3 genes are responsible for the condition, with CCM3 being the most severe: lesions that are both more numerous and larger in size. My primary objective to investigate the reason behind why the CCM3 condition is so much more severe than CCM1/CCM2 by determining the differences between their functions, which can be achieved by identifying the genes that function in the CCM3 pathways, independently of the CCM1/CCM2. To accomplish this, I propose using mutagenesis to look for genetic changes that are capable of either mimicking or suppressing the CCM condition caused by CCM3 loss-of-function. DNA sequencing will identify the genes that were mutated, and yield a list of genes involved in the CCM3 condition. This list represents new therapeutic approaches for drug discovery and/or synthesis specific to the CCM3 condition that should prevent the lesions from forming altogether, and have the benefit of being much lower risk than brain surgery."
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428729
Name
Cheng Ran
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidation of the Signaling Pathways involved in Human Cerebral Cavernous Malformations for the purpose of Therapeutics
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Disease; Caenorhabditis Elegans; Cerebral Cavernous Malformations; Developmental Biology; Genetic Screen; Molecular Genetics; Signaling Pathways; Therapeutic Discovery; Vasculature
Abstract
"Cerebral Cavernous Malformations (CCMs) are recurrent malformations (lesions) of the brain and spinal cord caused by leaking blood vessels. CCMs have symptoms that mimic neurodegeneration, and predisposes patients to a lifetime risk of stroke and epilepsy. The only available treatment is brain surgery to remove the lesion, but this is high risk and sometimes impossible if the lesions are deeper in the brain, which highlights a need for new treatments that are more effective, lower risk, and potentially preventative. Loss-of-function mutations in the CCM1, CCM2, and CCM3 genes are responsible for the condition, with CCM3 being the most severe: lesions that are both more numerous and larger in size. My primary objective to investigate the reason behind why the CCM3 condition is so much more severe than CCM1/CCM2 by determining the differences between their functions, which can be achieved by identifying the genes that function in the CCM3 pathways, independently of the CCM1/CCM2. To accomplish this, I propose using mutagenesis to look for genetic changes that are capable of either mimicking or suppressing the CCM condition caused by CCM3 loss-of-function. DNA sequencing will identify the genes that were mutated, and yield a list of genes involved in the CCM3 condition. This list represents new therapeutic approaches for drug discovery and/or synthesis specific to the CCM3 condition that should prevent the lesions from forming altogether, and have the benefit of being much lower risk than brain surgery."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheng, Ran
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~